Latest findings challenge behavioural approaches to the management of antipsychotic-induced weight gain
Abstract
Obesity is a major health problem among people with severe mental illness, linked to increased risk of chronic diseases and reduced life expectancy. This is attributable to a combination of factors, including lifestyle, social circumstances, medication side-effects and the illness itself. Second-generation antipsychotics are particularly associated with weight gain, affecting treatment adherence, symptoms and quality of life.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.